Arcutis Biotherapeutics
ARQT
63 hedge funds and large institutions have $1.02B invested in Arcutis Biotherapeutics in 2020 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 31 increasing their positions, 10 reducing their positions, and 4 closing their positions.
210% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 10
175% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 4
13% more funds holding
Funds holding: 56 → 63 (+7)
2.52% more ownership
Funds ownership: 88.51% → 91.03% (+2.5%)
0% less capital invested
Capital invested by funds: $1.02B → $1.02B (-$3.69M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$13.1M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12.8M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.56M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$2.19M |
| 5 |
State Street
Boston,
Massachusetts
|
+$2.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$4.96M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
-$4.7M |
| 3 |
PC
Polar Capital
London,
United Kingdom
|
-$2.67M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.02M |
| 5 |
Renaissance Technologies
New York
|
-$838K |
ARQT Hedge Fund Activity: Q3 2020 in Review
63 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q3 2020, worth a combined $1.02B — down 0.36% from $1.02B a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new ARQT positions and 4 closed out — a net gain of 7 holders — while 31 added to existing stakes and 10 trimmed.
The largest buyer was BlackRock, adding an estimated $13.1M. The largest seller was Omega Fund Management, cutting an estimated $4.96M.
- 63 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q3 2020, up from 56 in Q2 2020.
- Funds reported $1.02B of Arcutis Biotherapeutics stock for Q3 2020, down 0.36% quarter-over-quarter.
- 11 funds opened new Arcutis Biotherapeutics positions in Q3 2020 and 4 closed out, a net change of +7 holders.
- The largest Arcutis Biotherapeutics buyer in Q3 2020 was BlackRock, an estimated $13.1M added.
- The largest Arcutis Biotherapeutics seller in Q3 2020 was Omega Fund Management, an estimated $4.96M sold.
Based on aggregated 13F filings for Q3 2020.